FFAR1 is involved in both the acute and chronic effects of palmitate on insulin secretion

Endocrinology

Volumn 154, Issue 11, 2013, Pages 4078-4088

  Kristinsson, Hjalti ^a   Smith, David M ^b   Bergsten, Peter ^a   Sargsyan, Ernest ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANT 203; FASIGLIFAM; G PROTEIN COUPLED RECEPTOR 40; INSULIN; PALMITIC ACID; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL FUNCTION; CYTOTOXICITY; DOWN REGULATION; INSULIN RELEASE; INSULINOMA; INTRACELLULAR SIGNALING; LONG TERM EXPOSURE; MOUSE; NONHUMAN; OXIDATION; PLEIOTROPY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

BENZOFURANS; CELL LINE; GENE EXPRESSION REGULATION; GLUCOSE; HUMANS; HYDRAZONES; INSULIN; ISLETS OF LANGERHANS; MOLECULAR STRUCTURE; PALMITIC ACID; PYRIMIDINES; RECEPTORS, G-PROTEIN-COUPLED; RNA, SMALL INTERFERING; SULFONES;

EID: 84886511483     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1352     Document Type: Article

References (55)

1. Henquin JC, Ravier MA, Nenquin M, Jonas JC, Gilon P. Hierarchy of the β-cell signals controlling insulin secretion. Eur J Clin Invest. 2003;33(9): 742-750.
2. Martoglio B, Dobberstein B. Snapshots of membrane-translocating proteins. Trends Cell Biol. 1996;6(4): 142-147.
3. Kashyap S, Belfort R, Gastaldelli A, et al. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes. 2003;52(10): 2461-2474.
4. Turk J, Gross RW, Ramanadham S. Amplification of insulin secretion by lipid messengers. Diabetes. 1993;42(3): 367-374.
5. Zhou YP, Grill V. Long term exposure to fatty acids and ketones inhibits B-cell functions in human pancreatic islets of Langerhans. J Clin Endocrinol Metab. 1995;80(5): 1584-1590.
6. Maedler K, Spinas GA, Dyntar D, Moritz W, Kaiser N, Donath MY. Distinct effects of saturated and monounsaturated fatty acids on β-cell turnover and function. Diabetes. 2001;50(1): 69-76.
7. Boucher A, Lu D, Burgess SC, et al. Biochemical mechanism of lipid-induced impairment of glucose-stimulated insulin secretion and reversal with a malate analogue. J Biol Chem. 2004;279(26): 27263-27271.
8. Sargsyan E, Bergsten P. Lipotoxicity is glucose-dependent in INS-1E cells but not in human islets and MIN6 cells. Lipids Health Dis. 2011;10:115.
9. CnopM,Hannaert JC, Hoorens A, Eizirik DL, PipeleersDG.Inverse relationship between cytotoxicity of free fatty acids in pancreatic islet cells and cellular triglyceride accumulation. Diabetes. 2001; 50(8): 1771-1777.
10. Moffitt JH, Fielding BA, Evershed R, Berstan R, Currie JM, Clark A. Adverse physicochemical properties of tripalmitin in β cells lead to morphological changes and lipotoxicity in vitro. Diabetologia. 2005;48(9): 1819-1829.
11. Lupi R, Dotta F, Marselli L, et al. Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that β-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. Diabetes. 2002; 51(5): 1437-1442.
12. Deeney JT, Gromada J, Hoy M, et al. Acute stimulation with long chain acyl-CoA enhances exocytosis in insulin-secreting cells (HIT T-15 and NMRI β-cells). J Biol Chem. 2000;275(13): 9363-9368.
13. Larsson O, Deeney JT, Branstrom R, Berggren PO, Corkey BE. Activation of the ATP-sensitive K+ channel by long chain acyl-CoA. A role in modulation of pancreatic β-cell glucose sensitivity. J Biol Chem. 1996;271(18): 10623-10626.
14. Itoh Y, Kawamata Y, Harada M, et al. Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40. Nature. 2003;422(6928): 173-176.
15. Soga T, Ohishi T, Matsui T, et al. Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein- coupled receptor. Biochem Biophys Res Commun. 2005; 326(4): 744-751.
16. Briscoe CP, Tadayyon M, Andrews JL, et al. The orphan G proteincoupled receptorGPR40is activated bymediumand long chain fatty acids. J Biol Chem. 2003;278(13): 11303-11311.
17. Fujiwara K, Maekawa F, Yada T. Oleic acid interacts with GPR40 to induce Ca2+ signaling in rat islet β-cells: mediation by PLC and L-type Ca2+ channel and link to insulin release. Am J Physiol Endocrinol Metab. 2005;289(4):E670-E677.
18. Shapiro H, Shachar S, Sekler I, Hershfinkel M, Walker MD. Role of GPR40 in fatty acid action on the β cell line INS-1E. Biochem Biophys Res Commun. 2005;335(1): 97-104.
19. Steneberg P, Rubins N, Bartoov-Shifman R, WalkerMD,Edlund H. The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metab. 2005;1(4): 245-258.
20. Brownlie R, Mayers RM, Pierce JA, Marley AE, Smith DM. The long-chain fatty acid receptor, GPR40, and glucolipotoxicity: investigations using GPR40-knockout mice. Biochem Soc Trans. 2008;36(Pt 5): 950-954.
21. Wu J, Sun P, Zhang X, et al. Inhibition of GPR40 protects MIN6 β-cells from palmitate-induced ER stress and apoptosis. J Cell Biochem. 2012;113(4): 1152-1158.
22. KebedeM,Alquier T, LatourMG,SemacheM,Tremblay C, Poitout V. The fatty acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding. Diabetes. 2008;57(9): 2432-2437.
23. Lan H, Hoos LM, Liu L, et al. Lack of FFAR1/GPR40 does not protect mice from high-fat diet-induced metabolic disease. Diabetes. 2008;57(11): 2999-3006.
24. Latour MG, Alquier T, Oseid E, et al. GPR40 is necessary but not sufficient for fatty acid stimulation of insulin secretion in vivo. Diabetes. 2007;56(4): 1087-1094.
25. Nagasumi K, Esaki R, Iwachidow K, et al. Overexpression of GPR40 in pancreatic β-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice. Diabetes. 2009;58(5): 1067-1076.
26. Lin DC, Zhang J, Zhuang R, et al.AMG837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents. PLoS One. 2011;6(11):e27270.
27. Luo J, Swaminath G, Brown SP, et al. A potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents. PLoS One. 2012;7(10):e46300.
28. Tsujihata Y, Ito R, Suzuki M, et al. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats. J Pharmacol Exp Ther. 2011;339(1): 228-237.
29. Yashiro H, Tsujihata Y, Takeuchi K, Hazama M, Johnson PR, Rorsman P. The effects of TAK-875, a selective G protein-coupled receptor 40/free fatty acid 1 agonist, on insulin and glucagon secretion in isolated rat and human islets. J Pharmacol Exp Ther. 2012; 340(2): 483-489.
30. Araki T, Hirayama M, Hiroi S, Kaku K. GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes. Diabetes Obes Metab. 2012;14(3): 271-278.
31. Burant CF, Viswanathan P, Marcinak J, et al. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2012; 379(9824): 1403-1411.
32. Leifke E, Naik H,WuJ, Viswanathan P, et al.Amultiple-ascendingdose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes. Clin Pharmacol Ther. 2012;92(1): 29-39.
33. Naik H, Vakilynejad M, Wu J, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers. J Clin Pharmacol. 2012; 52(7): 1007-1016.
34. Sasaki S, Kitamura S, Negoro N, et al. Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists. J Med Chem. 54(5): 1365-1378.
35. Sargsyan E, Ortsater H, Thorn K, Bergsten P. Diazoxide-induced β-cell rest reduces endoplasmic reticulum stress in lipotoxic β-cells. J Endocrinol. 2008;199(1): 41-50.
36. Bergsten P, Hellman B. Glucose-induced amplitude regulation of pulsatile insulin secretion from individual pancreatic islets. Diabetes. 1993;42(5): 670-674.
37. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitativePCRand the 2[-δδ C(T)] method. Methods. 2001;25(4): 402-408.
38. Mensink M, Blaak EE, van Baak MA, Wagenmakers AJ, Saris WH. Plasma free fatty acid uptake and oxidation are already diminished in subjects at high risk for developing type 2 diabetes. Diabetes. 2001;50(11): 2548-2554.
39. Del Guerra S, Bugliani M, D'Aleo V, et al. G-protein-coupled receptor 40 (GPR40) expression and its regulation in human pancreatic islets: the role of type 2 diabetes and fatty acids. Nutr Metab Cardiovasc Dis. 20(1): 22-25.
40. Tomita T, Masuzaki H, Iwakura H, et al. Expression of the gene for a membrane-bound fatty acid receptor in the pancreas and islet cell tumours in humans: evidence for GPR40 expression in pancreatic β cells and implications for insulin secretion. Diabetologia. 2006; 49(5): 962-968.
41. Ferdaoussi M, Bergeron V, Zarrouki B, et al. G protein-coupled receptor (GPR)40-dependent potentiation of insulin secretion in mouse islets is mediated by protein kinase D1. Diabetologia. 55(10): 2682-2692.
42. Salehi A, Flodgren E, Nilsson NE, et al. Free fatty acid receptor 1 [FFA(1)R/GPR40] and its involvement in fatty-acid-stimulated insulin secretion. Cell Tissue Res. 2005;322(2): 207-215.
43. Alquier T, Peyot ML, Latour MG, et al. Deletion of GPR40 impairs glucose-induced insulin secretion in vivo in mice without affecting intracellular fuel metabolism in islets. Diabetes. 2009;58(11): 2607-2615.
44. Lin DC, Guo Q, Luo J, et al. Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor. Mol Pharmacol. 2012;82(5): 843-859.
45. Barg S, Eliasson L, Renstrom E, Rorsman P.Asubset of 50 secretory granules in close contact with L-type Ca2+ channels accounts for first-phase insulin secretion in mouse β-cells. Diabetes. 2002; 51(suppl 1):S74-S82.
46. Henquin JC, Ishiyama N, Nenquin M, RavierMA,Jonas JC. Signals and pools underlying biphasic insulin secretion. Diabetes. 2002; 51(suppl 1):S60-S67.
47. Aston-Mourney K, Proietto J, Morahan G, Andrikopoulos S. Too much of a good thing: why it is bad to stimulate the β cell to secrete insulin. Diabetologia. 2008;51(4): 540-545.
48. Wagner R, Kaiser G, Gerst F, et al. Reevaluation of fatty acid receptor 1 as a drug target for the stimulation of insulin secretion in humans. Diabetes. 2013;62(6): 2106-2111.
49. Briaud I, Harmon JS, Kelpe CL, Segu VB, Poitout V. Lipotoxicity of the pancreatic β-cell is associated with glucose-dependent esterification of fatty acids into neutral lipids. Diabetes. 2001;50(2): 315-321.
50. Paumen MB, Ishida Y, Muramatsu M, Yamamoto M, Honjo T. Inhibition of carnitine palmitoyltransferase I augments sphingolipid synthesis and palmitate-induced apoptosis. J Biol Chem. 1997; 272(6): 3324-3329.
51. Sol ER, Sargsyan E, Akusjarvi G, Bergsten P. Glucolipotoxicity in INS-1E cells is counteracted by carnitine palmitoyltransferase 1 over-expression. Biochem Biophys Res Commun. 2008;375(4): 517-521.
52. Iizuka K, Nakajima H, Namba M, et al. Metabolic consequence of long-term exposure of pancreatic β cells to free fatty acid with special reference to glucose insensitivity. Biochim Biophys Acta. 2002; 1586(1): 23-31.
53. Newsholme P, Haber EP, Hirabara SM, et al. Diabetes associated cell stress and dysfunction: role of mitochondrial and non-mitochondrial ROS production and activity. J Physiol. 2007;583(Pt 1): 9-24.
54. HuH,HeLY,GongZ, et al.Anovel class of antagonists for the FFAs receptor GPR40. Biochem Biophys Res Commun. 2009;390(3): 557-563.
55. Zhao YF, Pei J, Chen C. Activation of ATP-sensitive potassium channels in rat pancreatic β-cells by linoleic acid through both intracellular metabolites and membrane receptor signalling pathway. J Endocrinol. 2008;198(3): 533-540.